Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology

  • Andrea B. Galosi | Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Erika Palagonia Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Simone Scarcella Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Alessia Cimadamore Division of Pathology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Vito Lacetera Division of Urology, Azienda Ospedaliera Marche Nord, Pesaro, Italy.
  • Rocco F. Delle Fave Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Angelo Antezza Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.
  • Lucio Dell'Atti Division of Urology, School of Medicine, Università Politecnica delle Marche, Ancona, Italy.


Reasons why significant prostate cancer is still missed in early stage were investigated at the 22nd National SIEUN (Italian Society of integrated diagnostic in Urology, Andrology, Nephrology) congress took place from 30th November to 1st December 2020, in virtual modality. Even if multiparametric magnetic resonance (MR) has been introduced in the clinical practice several, limitations are emerging in patient with regular digital rectal examination (DRE) and serum prostate specific antigen (PSA) levels approaching the normal limits. The present paper summarizes highlights observed in those cases where significant prostate cancer may be missed by PSA or imaging and DRE. The issue of multidisciplinary interest had been subdivided and deepened under four main topics: biochemical, clinical, pathological and radiological point of view with a focus on PI-RADS 3 lesions.



PlumX Metrics


Download data is not yet available.


Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, et al. New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. Front Oncol. 2018;8:653. DOI:

Mottet N, Bastian P, Bellmunt J, van den Bergh R, Bolla M, van Casteren N, et al. EAU - EANM - ESTRO - ESUR - SIOG: Guidelines on Prostate Cancer. Eur Assoc Urol. 2020;1–182.

Lambert E, Goossens M, Palagonia E, Vollemaere J, Mazzone E, Dell’Oglio P, et al. Changes in serum PSA after endoscopic enucleation of the prostate are predictive for the future diagnosis of prostate cancer. World J Urol. 2020 Sep; DOI:

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004 May;350:2239–46. DOI:

Maselli G, Tucci G, Mazzaferro D, Ettamimi A, Sbrollini G, Cordari M, et al. Prolonged antibiotic therapy increases risk of infection after transrectal prostate biopsy: a case report after pancreasectomy and review of the literature. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2014 ;86:387–8. DOI:

Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman K V., et al. Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. J Urol [Internet]. 2018;199:947–53. DOI:

Vickers AJ, Ulmert D, Sjoberg DD, Bennette CJ, Björk T, Gerdtsson A, et al. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study. BMJ. 2013;346. DOI:

Carter HB, Ferrucci L, Kettermann A, Landis P, Wright EJ, Epstein JI, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521–7. DOI:

Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An Empirical Evaluation of Guidelines on Prostate-specific Antigen Velocity in Prostate Cancer Detection. 2011;103:0–7. DOI:

Fandella A, Scattoni V, Galosi A, Pepe P, Fiorentino M, Gaudiano C, et al. Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights. Anticancer Res. 2017 Feb;37:413–24. DOI:

Martino P, Galosi AB, Bitelli M, Consonni P, Fiorini F, Granata A, et al. Practical recommendations for performing ultrasound scanning in the urological and andrological fields. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2014 ;86:56–78. DOI:

Pagniez MA, Kasivisvanathan V, Puech P, Drumez E, Villers A, Olivier J. Predictive Factors of Missed Clinically Significant Prostate Cancers in Men with Negative Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis. J Urol. 2020;204:24–32. DOI:

Roscigno M, Stabile A, Lughezzani G, Pepe P, Galosi AB, Naselli A, et al. The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification? Clin Genitourin Cancer. 2020 Dec;18:e698–704. DOI:

Bhat NR, Vetter JM, Andriole GL, Shetty AS, Ippolito JE, Kim EH. Magnetic Resonance Imaging-Defined Prostate-Specific Antigen Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy. Urology. 2019;126:152–7. DOI:

Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN, et al. What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol. 2017;72:250–66. DOI:

Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int. 2016 ;117:401–8. DOI:

Panebianco V, Barchetti G, Simone G, Del Monte M, Ciardi A, Grompone MD, et al. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What’s Next? [Figure presented]. Eur Urol [Internet]. 2018;74:48–54. DOI:

Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781–93. DOI:

Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, et al. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol. 2020;38:2798–811. DOI:

Zhen JT, Syed J, Nguyen KA, Leapman MS, Agarwal N, Brierley K, et al. Genetic testing for hereditary prostate cancer: Current status and limitations. Cancer. 2018;124:3105–17. DOI:

Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis. Prostate. 2019;79:880–95. DOI:

Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J Androl. 2012;14:409–14. DOI:

Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated risk of prostate cancer among men with lynch syndrome. J Clin Oncol. 2013;31:1713–8. DOI:

Ostrander EA, Stanford JL. Genetics of prostate cancer: Too many loci, too few genes. Am J Hum Genet. 2000;67:1367–75. DOI:

Carroll PR, Parsons JK, Andriole G, Bahnson RR, Barocas DA, Castle EP, et al. Prostate cancer early detection, version 2.2015: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2015;13:1534–61. DOI:

Gasparrini S, Cimadamore A, Mazzucchelli R, Scarpelli M, Massari F, Raspollini MR, et al. Pathology and molecular updates in tumors of the prostate: towards a personalized approach. Expert Rev Mol Diagn. 2017;17:781–9. DOI:

Dell’Atti L, Galosi AB. Safety of transrectal ultrasound-guided prostate biopsy in patients affected by Crohn’s disease. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2017 ;89:106–9. DOI:

Oon SF, Watson RW, O’Leary JJ, Fitzpatrick JM. Epstein criteria for insignificant prostate cancer. BJU Int. 2011;108:518–25. DOI:

Mazzucchelli R, Galosi AB, Lopez-Beltran A, Scarpelli M, Cheng L, Montironi R. Pathological issues in biopsy specimens of men with prostate cancer eligible for active surveillance. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2014 ;86:314–8. DOI:

Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 ;40:244–52. DOI:

Matoso A, Epstein JI. Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2019;74:135–45. DOI:

Lacetera V, Cervelli B, Cicetti A, Gabrielloni G, Montesi M, Morcellini R, et al. MRI/US fusion prostate biopsy: Our initial experience. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2016 ;88:296–9. DOI:

Galosi AB, Maselli G, Sbrollini G, Donatelli G, Montesi L, Tallè M, et al. Cognitive zonal fusion biopsy of the prostate: Original technique between target and saturation. Arch Ital di Urol Androl organo Uff [di] Soc Ital di Ecogr Urol e Nefrol. 2016 ;88:292–5. DOI:

Cimadamore A, Scarpelli M, Raspollini MR, Doria A, Galosi AB, Massari F, et al. Prostate cancer pathology: What has changed in the last 5 years. Urologia. 2020 ;87::3–10. DOI:

Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, et al. Prostate cancer: from Gleason scoring to prognostic grade grouping. Expert Rev Anticancer Ther. 2016;16:433–40. DOI:

Magi-Galluzzi C, Montironi R, Epstein JI. Contemporary Gleason grading and novel Grade Groups in clinical practice. Curr Opin Urol. 2016;26:488–92. DOI:

Kamoun A, Cancel-Tassin G, Fromont G, Elarouci N, Armenoult L, Ayadi M, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Ann Oncol. 2018;29(8):1814–21. DOI:

Sauter G, Steurer S, Clauditz TS, Krech T, Wittmer C, Lutz F, et al. Clinical utility of quantitative gleason grading in prostate biopsies and prostatectomy specimens. Eur Urol. 2016;69(4):592–8. DOI:

Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Helleman J, Roobol MJ, et al. Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis. Mod Pathol [Internet]. 2019;32:139–46. DOI:

Roberts JA, Zhou M, Park YW, Ro JY. Intraductal carcinoma of prostate: A comprehensive and concise review. Korean J Pathol. 2013;47:307–15. DOI:

Zong Y, Montironi R, Massari F, Jiang Z, Lopez-Beltran A, Wheeler TM, et al. Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives. Eur Urol Focus. 2020 Oct DOI:

Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, et al. Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories. Eur Urol. 2017 ;72:492–5. DOI:

Silva MM da J, Matheus WE, Garcia PV, Stopiglia RM, Billis A, Ferreira U, et al. Characterization of reactive stroma in prostate cancer: involvement of growth factors, metalloproteinase matrix, sexual hormones receptors and prostatic stem cells. Int Braz J Urol. 2015;41:849–58. DOI:

Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008 ;32:65–71. DOI:

Abouhashem NS, Salah S. Differential expression of NKX 3.1 and HOXB 13 in bone metastases originating from prostatic carcinoma among the Egyptian males. Pathol Res Pract. 2020 ;216:153221. DOI:

Paner GP, Aron M, Hansel DE, Amin MB. Non-epithelial neoplasms of the prostate. Histopathology. 2012;60:166–86. DOI:

Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet [Internet]. 2017;389:815–22. DOI:

Rouvière O, Puech P, Renard-Penna R, Claudon M, Roy C, Mège-Lechevallier F, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. Lancet Oncol. 2019;20:100–9. DOI:

Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol [Internet]. 2019;75:712–20. DOI:

Galosi AB, Dell’Atti L, Bertaccini A, Gion M, Francavilla S, Ferretti S, et al. Clinical evaluation of the iXip index to reduce prostate re-biopsies. Cancer Treat Res Commun. 2018;16:59–63. DOI:

Quon JS, Moosavi B, Khanna M, Flood TA, Lim CS, Schieda N. False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance. Insights Imaging. 2015;6:449–63. DOI:

Sonn GA, Fan RE, Ghanouni P, Wang NN, Brooks JD, Loening AM, et al. Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists. Eur Urol Focus [Internet]. 2019;5:592–9. DOI:

Chatterjee A, Thomas S, Oto A. Prostate MR: pitfalls and benign lesions. Abdom Radiol [Internet]. 2020;45:2154–64. DOI:

Wang Z, Zhao W, Shen J, Jiang Z, Yang S, Tan S, et al. PI-RADS version 2.1 scoring system is superior in detecting transition zone prostate cancer: a diagnostic study. Abdom Radiol [Internet]. 2020;(0123456789). DOI:

Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 ;69:16–40. DOI:

Yang S, Zhao W, Tan S, Zhang Y, Wei C, Chen T, et al. Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy. Transl Androl Urol. 2020;9:1252–61. DOI:

Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G, et al. Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus [Internet]. 2020;6:463–78. DOI:

Byun J, Park KJ, Kim M hyun, Kim JK. Direct Comparison of PI-RADS Version 2 and 2.1 in Transition Zone Lesions for Detection of Prostate Cancer: Preliminary Experience. J Magn Reson Imaging. 2020;52(2):577–86. DOI:

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017;120:631–8. DOI:

Ullrich T, Quentin M, Arsov C, Schmaltz AK, Tschischka A, Laqua N, et al. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate. J Urol. 2018;199:691–8. DOI:

Venderink W, van Luijtelaar A, Bomers JGR, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, et al. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer. Eur Urol. 2018;73:353–60. DOI:

Schoots IG. MRI in early prostate cancer detection: How to manage indeterminate or equivocal PI-RADS 3 lesions? Transl Androl Urol. 2018;7:70–82. DOI:

van der Sar ECA, Kasivisvanathan V, Brizmohun M, Freeman A, Punwani S, Hamoudi R, et al. Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer. Eur Urol Focus 2019;5:62–8. DOI:

Frye TP, George AK, Kilchevsky A, Maruf M, Siddiqui MM, Kongnyuy M, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol 2017;197:640–6. DOI:

SIEUN Congress 2020: Original Papers, Reviews and Case Reports
Prostate cancer; Prostate needle biopsy; Radical prostatectomy; Diagnosis; Magnetic Resonance Imaging
  • Abstract views: 117

  • PDF: 79
How to Cite
Galosi, A. B., Palagonia, E., Scarcella, S., Cimadamore, A., Lacetera, V., Delle Fave, R. F., Antezza, A., & Dell’Atti, L. (2021). Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. Archivio Italiano Di Urologia E Andrologia, 93(1), 92-100.